Aroa Biosurgery Limited has published interim data from its Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR) in the Journal of Trauma and Injury, showing that its Myriad Matrix and Myriad Morcells bioscaffolds achieved vascularized tissue coverage in complex trauma wounds in a median of 22.5 days. The prospective multicenter study tracked 49 patients and 61 wound sites at four Level 1 trauma centers in the United States, with no device-related complications reported. The findings position the New Zealand-based bioscaffold developer’s Myriad platform as both clinically effective and economically competitive versus existing soft tissue matrices.

What this MASTRR update reveals about bioscaffold performance in trauma care

While bioscaffolds have long played a role in wound healing and soft tissue reconstruction, their penetration into trauma care remains limited by cost concerns, performance variability, and surgical workflow compatibility. The latest MASTRR dataset offers real-world validation in the most demanding trauma environments—Level 1 trauma centers—where wounds tend to be large, contaminated, and surgically challenging.

Industry observers note that the reported 22.5-day median to full vascularized tissue coverage, often with a single application of Myriad, aligns with surgical expectations in complex reconstructions. However, the low rate of device-related complications may matter more in this setting. Trauma surgeons operating under constrained timelines and infection risks tend to prioritize reliability and ease of use over marginal differences in closure speed.

The fact that Myriad was used effectively across 61 complex defects, with no device-related adverse events, enhances its risk–benefit profile. Importantly, clinicians tracking the bioscaffold field say this interim data builds on prior surgical impressions—offering structured evidence to support product selection decisions in trauma protocols.

Why cost benchmarking in trauma bioscaffolds matters more than ever in 2026

The study’s inclusion of a published-data comparison between Myriad and other bioscaffolds reflects an increasingly competitive dynamic in trauma care economics. The trauma sector has long been viewed as a difficult entry point for high-cost regenerative materials, especially when reimbursement pathways are fragmented and procedural variability is high.

In this context, Myriad’s reported lower cost per square centimeter relative to alternatives may not just support adoption—it could expand the bioscaffold addressable market. Aroa Biosurgery estimates the total addressable U.S. trauma opportunity at approximately USD 450 million annually, covering over 140,000 procedures. That figure includes acute care surgeries for open fractures, abdominal trauma, dehiscence management, and infected or contaminated wounds. The implication is clear: price-sensitive buyers, particularly in trauma surgery units balancing volume and resource constraints, may now reconsider bioscaffold inclusion in their standard operative protocols.

Surgeons and hospital administrators have long sought solutions that meet the dual bar of clinical effectiveness and cost neutrality. If Myriad can deliver on both fronts, it could accelerate procedural integration in a market segment that has historically defaulted to traditional closure techniques, skin grafts, or delayed closure with negative pressure devices.

How Myriad fits into the broader AROA ECM platform evolution

For Aroa Biosurgery, the Myriad product line is just one of several applications built atop the company’s proprietary AROA ECM platform—a bioscaffold derived from ovine forestomach matrix. Unlike synthetic meshes or single-component matrices, the AROA ECM platform emphasizes a full-thickness extracellular matrix approach, preserving biochemical signaling and structural cues to guide tissue remodeling.

The company’s decision to pursue a registry-based, multicenter prospective study such as MASTRR signals a long-term strategy aimed at building platform-level clinical evidence across indications. The November 2025 publication on pilonidal sinus disease further validates the platform’s versatility, showing performance in a completely different surgical context: reconstructive outpatient procedures where quality of life and cost savings are primary endpoints.

Clinicians tracking regenerative matrices note that platform consistency is becoming a more important differentiator in formulary decisions. Hospitals are increasingly standardizing across fewer vendors, preferring platforms that work across trauma, hernia, wound care, and reconstruction rather than piecemeal products. The publication of MASTRR’s trauma cohort may therefore support broader procurement conversations across departments and specialties.

Where the regulatory and reimbursement pathways still face friction

Despite growing clinical evidence, the U.S. trauma segment still presents regulatory and reimbursement friction for new soft-tissue reconstruction products. While Myriad’s safety and effectiveness data strengthen its clinical positioning, reimbursement pathways remain influenced by procedural coding variability, off-label use patterns, and local medical necessity interpretations.

Myriad is not yet formally FDA-approved for all trauma-specific indications, which means some applications may fall into the realm of surgeon-directed use under broader wound healing codes. Regulatory watchers suggest this could limit speed of adoption in some large hospital systems, particularly those requiring narrowly defined clinical justification for bioscaffold use.

At the same time, reimbursement for bioscaffolds in trauma cases often hinges on DRG (Diagnosis Related Group) bundling and value analysis committee approvals. In high-volume trauma centers, cost–effectiveness becomes a gating factor for widespread adoption. The MASTRR dataset could support these institutional review processes, but third-party validation or health-economic modeling may be needed to accelerate broader inclusion in standardized care pathways.

What this changes for surgical practice and competitive positioning

With over 116 peer-reviewed studies now supporting the AROA ECM platform, Aroa Biosurgery has gradually shifted from a niche regenerative materials player into a broader surgical platform company. Myriad’s trauma performance data may enable the company to capture share in a traditionally difficult market segment, where adoption depends on both clinician trust and economic viability.

Competitor matrices in the trauma space include products from LifeCell (AlloDerm), Integra LifeSciences, Smith & Nephew, and others, many of which are positioned at higher price points or require more complex handling protocols. If Myriad’s single-application outcomes and economic profile continue to hold, it could disrupt procurement decisions and prompt revisits of formulary inclusion, especially in centers looking to reduce biosurgical SKU fragmentation.

Clinicians focused on contaminated or infected trauma wounds may also benefit from further clarity on Myriad’s performance in biofilm-prone environments, which remain one of the most clinically vexing aspects of trauma wound management. That remains an open question, and additional subgroup data from MASTRR will be critical in validating the product’s role in infection-prone cases.

What comes next for MASTRR and soft tissue matrices in trauma

Aroa Biosurgery has signaled that the MASTRR study is ongoing and will continue enrolling patients to strengthen the dataset’s statistical power and subgroup granularity. Analysts expect future publications to explore long-term wound durability, reinjury rates, infection recurrence, and functional outcomes.

From a commercial strategy perspective, the publication cadence also serves to prime hospital decision-makers ahead of budget cycles. With U.S. trauma procedures growing slowly but steadily, fueled by aging infrastructure, violent injury trends, and comorbid patients, the demand for better soft tissue closure tools remains persistent—even as budgets remain tight.

The next key moment may come when Aroa submits a formal health economic analysis for publication or payer consideration. If Myriad’s value proposition can be quantified across different procedural settings—trauma, reconstructive, wound management—then platform adoption may accelerate beyond the surgical niche into hospital-wide supply chain planning.

  Aroa Biosurgery, AROA ECM, bioscaffold, MASTRR study, medical devices, Myriad Matrix, Myriad Morcells, soft tissue reconstruction, trauma surgery, wound healing